2018-03-08| Asia-Pacific

WuXi NextCODE and Google Cloud Collaborate on Genomics

by GeneOnline
Share To

WuXi NextCODE, a genomic information company, announced a partnership with Google Cloud to integrate its genomic data analysis platforms with the Google genomics and research tools. The partnership was announced at the Healthcare Information and Management Systems Society (HIMSS) annual meeting in Las Vegas this week.

With offices in Shanghai; Cambridge, Massachusetts; and Reykjavik, Iceland, WuXi NextCODE provides comprehensive solutions for managing and applying genomic data to improve healthcare and genomic research. The WuXi NextCODE platform was originally developed at deCODE genetics in Iceland to manage massive collection of genomic data. In 2013, deCODE spun out its branch, NextCODE, to focus on using the existing genomic data to find linkage with disease variants in human genome. NextCODE then was acquired by WuXi AppTec, a China- and US-based open access R&D platform, in 2015, and merged with its Shanghai-based WuXi Genome Center.

After the joint venture between WuXi AppTec and the Mayo Clinic on providing clinical diagnostic solution in China in January, WuXi NextCODE took a step forward to work with the data analysis expert, Google Cloud, to resolve the data-processing challenge scientists encounter in genomics. The partnership includes integration of Google genomics and research tools with WuXi’s platform, Google’s DeepVariant secondary analysis pipeline, and other open-source analysis tools available via Google Cloud.

WuXi NextCODE also plans to launch the first phase of the offering at the Bio-IT World Conference & Expo in Boston in May.


Image Source

© All rights reserved. Collaborate with us:
Related Post
Bayer Signs Up To Google Cloud To Boost Drug Discovery
Illumina Genomics Forum Highlights – President Obama, Novel Sequencer, Bill Gates
Bill Gates Speaks at the Illumina Genomics Forum
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
Comparing ESG Regulations in the U.S., the U.K., and the EU
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
Scroll to Top